Jarad Hayes connects biotech and pharma teams under FDA and pipeline pressure with the CROs and specialist operators who deliver — the day the pressure hits the record.
Public FDA, trial, and filing data, updated as it publishes — this is the market I watch.
- →FDA warns Eurofins SF Analytical Laboratories’ contract testing lab in Horsham, PA — inspectors find analysts omitted innumerable membrane-filtration microbial counts and logged only pour-plate results, with desiccated, cracked plates still recorded as passing, every drug product the CRO tested declared adulterated under CGMP (FDA, Oct 2026)
- →FDA lists a recall for Par Health’s argatroban injection, 22 lots pulled to the hospital and user level — particulate matter including cellulose, polystyrene, and stopper material triggers the Oct 13 recall of the heparin-induced-thrombocytopenia anticoagulant (FDA, Oct 2026)
- →EyePoint Pharmaceuticals’ pivotal Phase 3 LUCIA trial of Duravyu misses its primary endpoint against Eylea in wet age-related macular degeneration — the company ends both pivotal trials early and shares plunge more than 75% in premarket trading (EyePoint, Oct 2026)
- →Alcon agrees to acquire Neurotech Pharmaceuticals for $550 million plus contingent milestones, picking up Encelto, the only FDA-approved cell therapy for macular telangiectasia type 2 — CEO David Endicott calls the gene-therapy platform a complementary addition to Alcon’s retina pipeline (Alcon, Oct 2026)
Sourced from FDA warning letters and recalls, sponsor trial announcements, and company disclosures.
No deal to point at yet — so here’s exactly what I put in motion.
- Flagged sponsor → operator who fixes it When a warning letter, a 483, or a trial setback lands, the clock starts. I put the right CRO or quality specialist in the room while it’s still a problem — not yet a consent decree.
- CRO / specialist → the sponsors who just learned they need you If you run trials, remediate quality systems, or rescue programs for a living, I bring you the sponsors the day their problem becomes public record.
Building in the open. I’m working alongside myoProcess — a vetted B2B partner trusted across $1B+ in transactions — while I route my first introductions in this lane. My first closed match replaces this paragraph.
What I see in this market that outsiders miss.